Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

Haemophilia

Volumn 22, Issue 3, 2016, Pages 381-388

  Kavakli, K ^a   Smith, L ^b   Kuliczkowski, K ^c   Korth Bradley, J ^b   You, C W ^d   Fuiman, J ^b   Zupancic Salek S ^e   Abdul Karim, F ^f   Rendo, P ^b  

^a EGE UNIVERSITY   (Turkey)

^b PFIZER INC   (United States)

^c UNIVERSITY OF WROC AW   (Poland)

^d Eulji University   (South Korea)

^e KBC Zagreb   (Croatia)

^f Kuala Lumpur City Centre   (Malaysia)

Author keywords

BeneFIX; Factor IX; Haemophilia B; Pharmacokinetics; Prevention; Safety

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; COAGULATING AGENT; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANNUALIZED BLEEDING RATE; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING TIME; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UNDERDOSE; FEVER; HEADACHE; HEMAGGLUTINATION; HEMOPHILIA B; HUMAN; INCIDENCE; JOINT SWELLING; MALE; MULTICENTER STUDY; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SWELLING; THROMBOGENICITY; TOOTH PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HEMORRHAGE; METABOLISM; MIDDLE AGED; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958213246     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12878     Document Type: Article

References (29)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47
2. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus 2011; 9: 60-9
3. Fischer K, Steen CK, Petrini P et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36
4. Lucia JF, Aznar JA, Abad-Franch L et al. Prophylaxis therapy in haemophilia A: current situation in Spain. Haemophilia 2011; 17: 75-80
5. Jackson SC, Yang M, Minuk L et al. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Haemophilia 2014; 20: e199-204
6. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, Mclimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30
7. Delivery of Treatment for Haemophilia. Geneva, Switzerland: World Health Organization, 2002. Available at: http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf. Accessed November 11, 2014
8. Summary Report of UDC Activity, National Treatment/Clinical Characteristics (Hemophilia). Atlanta, GA: United States Centers for Disease Control and Prevention, 2011. Available at: https://www2a.cdc.gov/ncbddd/htcweb/UDC_Report/UDC_view1.asp?para1=NATION¶2=TREATH. Accessed January 5, 2015
9. Mondorf W, Kalnins W, Klamroth R. Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy. Haemophilia 2013; 19: 558-63
10. Harrison S, Adamson S, Bonam D et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998; 35: 4-10
11. Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20: 398-406
12. Rendo P, Smith L, Korth-Bradley JM, Charnigo RJ, Shafer F. Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-FIX) in moderately severe to severe (FIX ≤2%) hemophilia B patients [poster]. Presented at: Annual Congress of the European Association for Haemophilia and Allied Disorders; Warsaw, Poland: February 6-8, 2013
13. Berger K, Schopohl D, Hilger A et al. Research in haemophilia B-approaching the request for high evidence levels in a rare disease. Haemophilia 2015; 21: 4-20
14. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44
15. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haem-ophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9
16. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10
17. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36
18. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13
19. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012; 18: e140-53
20. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84
21. Schulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J, Blomback M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6: 1113-21
22. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8
23. Blankenship CS, Tortella BJ, Bruno M. BE EMPOWERED, a specialty pharmacy education program for hemophilia B patients, impacts adult joint bleeds and pediatric use of RICE. J Manag Care Pharm 2014; 20: 151-8
24. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23
25. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233-43
26. Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost 2013; 11: 2176-8
27. Rendo P, Shafer F, Korth-Bradley JM, Sivamurthy K, Korin J. Factors that influence the bleeding phenotype in severe hemophilic patients. Blood Coagul Fibrinolysis 2013; 24: 683-90
28. Berntorp E, Dolan G, Hermans C, Laffan M, Santagostino E, Tiede A. Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance? Haemophilia 2014; 20(Suppl. 7): 1-11
29. Rendo P, Shafer FE, Charnigo RJ et al. One-year assessment of coagulation markers and monitoring for thrombotic events in hemophilia B patients treatment with nonacog alfa [poster]. Presented at: World Federation of Hemophilia World Congress; Paris, France: July 8-12, 2012